| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ETRA |
| Uniprot No | P25101 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-427aa |
| 氨基酸序列 | METLCLRASFWLALVGCVISDNPERYSTNLSNHVDDFTTFRGTELSFLVT THQPTNLVLPSNGSMHNYCPQQTKITSAFKYINTVISCTIFIVGMVGNAT LLRIIYQNKCMRNGPNALIASLALGDLIYVVIDLPINVFKLLAGRWPFDH NDFGVFLCKLFPFLQKSSVGITVLNLCALSVDRYRAVASWSRVQGIGIPL VTAIEIVSIWILSFILAIPEAIGFVMVPFEYRGEQHKTCMLNATSKFMEF YQDVKDWWLFGFYFCMPLVCTAIFYTLMTCEMLNRRNGSLRIALSEHLKQ RREVAKTVFCLVVIFALCWFPLHLSRILKKTVYNEMDKNRCELLSFLLLM DYIGINLATMNSCINPIALYFVSKKFKNCFQSCLCCCCYQSKSLMTSVPM NGTSIQWKNHDQNNHNTDRSSHKDSMN |
| 预测分子量 | 75 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ETRA重组蛋白的示例参考文献(注：内容为虚构示例，实际文献需通过学术数据库查询)：
---
1. **文献名称**：*Expression and Purification of Recombinant ETRA Protein in E. coli*
**作者**：Smith A, et al.
**摘要**：本研究报道了在大肠杆菌系统中高效表达ETRA重组蛋白的方法，通过优化诱导条件和亲和层析技术实现高纯度蛋白制备，并验证了其体外配体结合活性。
2. **文献名称**：*Structural Insights into ETRA Receptor by X-ray Crystallography*
**作者**：Johnson B, et al.
**摘要**：利用X射线晶体学解析了ETRA重组蛋白的三维结构，揭示了其配体结合域的关键氨基酸残基，为靶向药物设计提供了结构基础。
3. **文献名称**：*Functional Analysis of ETRA in Cardiovascular Disease Models*
**作者**：Lee C, et al.
**摘要**：通过体外实验和小鼠模型证明，ETRA重组蛋白在调控血管收缩中发挥关键作用，其拮抗剂可能成为高血压治疗的潜在候选分子。
4. **文献名称**：*Optimized Purification Strategy for ETRA Fusion Proteins*
**作者**：Zhang D, et al.
**摘要**：开发了一种基于标签酶切和离子交换层析的新型纯化策略，显著提高了ETRA重组蛋白的产量和稳定性，适用于大规模工业化生产。
---
如需真实文献，建议通过PubMed、Web of Science或Google Scholar搜索关键词“ETRA recombinant protein”或相关领域术语。
ETRA recombinant protein is a biologically engineered molecule designed to mimic or modulate specific cellular processes, particularly those involving extracellular signaling pathways. The term "ETRA" often refers to engineered or edited versions of native proteins, such as receptors, enzymes, or growth factors, optimized for enhanced stability, solubility, or functional specificity. These proteins are typically produced using recombinant DNA technology, where target genes are cloned into expression vectors (e.g., bacterial, yeast, or mammalian systems) and purified for research or therapeutic applications.
The development of ETRA recombinant proteins stems from advancements in structural biology and protein engineering. By introducing targeted mutations (e.g., site-directed mutagenesis) or fusion tags (e.g., His-tags, Fc regions), researchers improve protein yield, ligand-binding affinity, or compatibility with diagnostic assays. For instance, ETRA variants of cytokine receptors or immune checkpoint proteins have been engineered to study ligand-receptor interactions or to develop biologics for cancer immunotherapy.
In therapeutics, ETRA recombinant proteins hold promise for treating diseases with dysregulated signaling pathways, such as autoimmune disorders, cancers, or rare genetic conditions. Examples include modified antibodies, decoy receptors, or enzyme replacement therapies. Their clinical utility often hinges on reduced immunogenicity and prolonged half-life compared to native proteins.
Current research focuses on optimizing delivery systems (e.g., nanoparticles) and exploring hybrid constructs (e.g., bispecific proteins). Despite challenges in scalability and cost, ETRA recombinant proteins remain pivotal in both basic research and translational medicine, bridging the gap between molecular insights and therapeutic innovation.
×
